HR-lymphomas disseminated less often than HR + / -or HR+ lymphomas ( P = .03), and their prognosis was more NLIKE HODGKIN'S disease, the non-Hodgkin's lym-
U phomas form a heterogeneous group of diseases with variable biologic behavior, ranging from well-differentiated lymphocytic lymphomas, which may be followed-up without treatment, to very aggressive forms of the disease, such as lymphoblastic lymphoma or Burkitt's lymphoma, which may be fatal within a few months. The type of treatment is chosen based on factors such as patient age and condition, presence of B symptoms, stage, and histologic subtype of lymphoma. However, these factors may fail to predict the biologic behavior, aggressive chemotherapy with its hazards may be given to patients not needing it, and follow-up without treatment, single agent chemotherapy, or radiotherapy may be selected for a patient in need of combination chemotherapy. None of the several histologic classifications available is universally accepted, and all staging examinations may miss small deposits of lymphoma.
Mature lymphocytes circulate continuously between the blood and lymphoid organs in the body.' In lymphatic tissues and at sites of chronic inflammation, lymphocytes leave the blood by selectively binding to specialized venules, so called high endothelial venules (HEV) .' This binding is mediated through homing receptor (HR) molecules that have been identified in the mouse, rat, and h~m a n .~.~ Although functionally mediating lymphocyte-endothelial cell interaction and therefore named as homing receptors, recent cloning data indicate that MEL-144efined homing receptor in mouse and Hermes-defined human receptor are structurally
In humans, 85 to 95 Kd glycoprotein class (CD44), defined by a Hermes-series of monoclonal antibodies (MoAbs), mediate lymphocyte binding to peripheral lymph node, mucosa-associated lymphatic tissues, and inflamed joint tissue (synovium)." Furthermore, expression of this glycoprotein class correlates well with the HEV-binding capacity of in vitro growing human lymphoma and lymphoblastoid cell lines. 6 An animal study has indicated that lymphomas, which bind well to HEV and thus possess functional HRs, disseminate hematogenously to all lymph node groups when injected intramuscularly into syngenic recipients, whereas nonbinding lymphomas do not spread via the blood, and involve only the nodes draining local tumor a t the site of injection." A small preliminary study with human lymphoma also sugfavorable ( P = .03), although they often had a large S phase fraction (SPF), indicating a rapid proliferation rate. A large SPF (greater than 12%) was strongly associated with an unfavorable histologic type in Working Formulation ( P = .0001) and poor survival (P = .006), whereas DNA aneuploidy was not. The 5-year survival rate corrected for intercurrent deaths was 61% in lymphomas with SPF less than 12% or with HR-, but only 15% if SPF was greater than 12% and HR+ ( P < .OOOl). In multivariate analysis stage (P < .OOl), SPF (P = .002) and HR ( P = .003) were the only independent prognostic factors. 0 1990 by The American Society of Hematology.
gested that H R expression correlates with the extent of lymph node in~olvement.'~ Picker et all4 found that Hermesdefined H R expression was higher in disseminated diffuse large cell lymphoma than in nondisseminated disease, but the difference did not achieve statistical significance, and no follow-up was available. Pals et on the other hand, found a highly significant correlation between the H R expression and dissemination of large cell lymphomas.
The nuclear DNA content of thousands of cells can be determined in a few minutes by flow cytometry. By this technique, an abnormal DNA content (DNA aneuploidy) has been found in about 30% of non-Hodgkin's lymphomas.16 Unlike in many epithelial cancers, DNA aneuploidy is probably not a major determinant of survival in lymphomas; but a large percentage of S phase cells, calculated by a simple procedure from the DNA histogram, has correlated well with poor prognosis.I7
In this study, tumors of 104 patients with nomHodgkin's lymphoma were analyzed for the expression of lymphocyte HRs, using Hermes-3 MoAb, and for the nuclear DNA content, and the data was correlated with histologic classification, clinical behavior of lymphoma, and the final outcome of the patients. The results indicate that H R negative (HR -) lymphomas seldom disseminate and have good prognosis even if they have a large fraction of proliferative cells, and that both H R and S phase fraction (SPF) are 
MATERIALS AND METHODS

Patients.
One hundred four consecutive adult cases (age over 16 years) with histologically diagnosed non-Hodgkin's lymphoma, treated in Turku University Central Hospital (Finland) from 1970 to 1980, with adequate staging examinations done and sufficient paraffin-embedded tumor material available were analyzed. Fiftysix (54%) of the patients were men and 48 women, the mean age at the diagnosis was 59 years (range, from 20 to 86 years). Twenty-two (21%) patients had B symptoms. All patients were followed-up for the minimum of 5 years (range, from 5 to 17 years) or until death.
Formalin-fixed and paraffinembedded tissue blocks were sectioned and stained with the Giemsa, hematoxylin and eosin, periodic acid-Schiff, methyl green and pyronin, and van Gieson methods. The original diagnoses were reviewed. Subclassification of the tumors was done according to the Working Formulation.'* Hematopoietic origin of lymphomas was confirmed with an MoAb against human common leukocyte antigen (DAKO, Glostrup, Denmark). MoAb against chicken T cells (3G6) used as serum-free culture supernatant served as a negative control antibody. The bound primary antibodies were visualized using the avidin-biotin complex technique (Vector Laboratories, Burlingame, CA) with I,l-diaminobenzidine as the chromogen.
Staging of the lymphomas was done according to the Ann Arbor classification system." The clinical status, chest x-ray, bipedal lymphography, bone marrow aspiration biopsy, and liver and spleen scans were usually done as staging examinations. Laparotomy was done only in cases with primary abdominal lymphoma. Thirty-one of the patients had stage I, 30 stage 11, 21 stage 111, and 22 stage IV disease at presentation. Because HRs are involved in lymphocyte binding to HEV at sites where lymphocytes exit the blood, the physiologic recirculation routes were taken into account when analyzing dissemination. Hematogenous spread of lymphoma was considered to be present if the dissemination pattern of lymphoma either at diagnosis, recurrence, or autopsy could not be explained by simple lymphatic drainage. For example, the presence of lymphoma in the Waldeyer's ring and in the cervical lymph nodes can be explained with lymphatic spread, whereas bilateral cervical node affision without detectable lymphoma in Waldeyer's ring or elsewhere in the head was considered as hematogenous spread.
Stage I and I1 patients were usually treated with radiotherapy (RT) or with the combination of radio-and chemotherapy, and stage 111 and IV patients were usually treated with chemotherapy only. Involved fields, the mantle, and the "inverted Y" fields were used, and the tumor dose was usually in the range from 4,000 to 4,500 cGy. The most commonly used chemotherapy combinations were COP (cyclophosphamide, vincristine, and prednisone) and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).
A representative paraffin embedded tissue block was chosen for flow cytometry. A 5-pm control section was cut immediately adjacent to the 50-pm section used for DNA content analysis for light microscopy to ascertain that tumor tissue was being analyzed. Paraffin was removed with xylene, and after rehydration in a series of decreasing concentrations of ethanol, a single cell suspension was prepared with 0.5% pepsin as described earlier." DNA was stained with propidium iodide.2' The resulting suspension was filtered through a silk mesh before flow cytometry.
Flow cytometry was done with a FACStar flow cytometer (BectonDickinson Immunocytometry Systems, Mountain View, CA). A 488-nm argon ion laser line run at 600 mW was used for fluorescence excitation. For each histogram, 20 x 10' particles were measured.
Histology. staging, and treatment.
Flow cytometry.
Histograms of good quality were obtained; the coefficient of variation (CV) of diploid peaks usually ranged from 3% to 6%. All samples were analyzed at least twice as described earlier. 22 If only one GI peak could be seen in the DNA histogram, lymphoma was considered to be diploid. Histograms with a skewed G1 peak or a G1 peak with a "shoulder" in repeated analyses were classified as near diploid. If two G1 peaks could be identified, the tumor was considered to be aneuploid. Examples of histograms are shown in Fig I . The DNA index was calculated from the ratio of the modal channel numbers of the aneuploid and diploid peaks. Tetraploid lymphomas had a G1 peak in the tetraploid region (4N, DNA index 1.9 to 2.1) and a corresponding G2/M peak in the octaploid region (8N). The peak with the least DNA content was considered to represent diploid cells. The percentage of S phase cells was calculated according to the rectangular method." No computer correction for possible cell debris was done. SPF was not calculated in six cases due to an overlapping aneuploid population, and in two cases due to excessive cell debris.
Staining of HRs. HR expression was determined using a monoclonal mouse antibody to human lymphocyte HR, Hermes-3, as serum-free culture supernatant. Hermes-3 has been shown to recognize a common determinant of CD44 class of HRs mediating lymphocyte binding to peripheral lymph node, mucosal, and synovial HEV." The production and specificity of this antibody have been described earlier." Hermes-3 was found to be the only antibody in the Hermes series that worked on paraffin-embedded tissue sections, but the staining patterns of Hermes-3 were comparable when tested on normal tonsils and over 20 different lymphoma specimens both on frozen and paraffin-embedded tissues (Fig 2) . Hermes-3 staining Coding. The patients were provided with a numerical code to prevent clinical data or survival information to interfere with histologic. DNA histogram. or HR expression classifications. The classifications were also done without knowledge of the results of the other analyses.
Stutisticd unulyses. Survival analysis was done using a BMDP computer program (BMDP Statistical Software, Department of Biomathematics, University of California Press, Los Angeles).
Survival was estimated with the product-limit method, and comparison of survival between groups was done using the generalized Wilcoxon test (BMDP IL). Both crude survival rate and survival rate corrected for known intercurrent deaths were calculated. The relative importance of prognostic factors was analyzed using Cox's proportional hazard model (BMDP 2L). Frequency Six HR-lymphomas were Ann Arbor stage I at the time of the diagnosis (P = .06). The patients with HR-lymphoma are described in detail in Table I . Sixty-four (61.5%) of the lymphomas were diploid and 12 (1 1 .5%) near-diploid. Twenty-eight (27%) lymphomas were clearly aneuploid (includes five tetraploid tumors). The DNA indices ranged from 1.00 to 2.07, and the most aneuploid peaks were in the hyperdiploid region (Fig 4) . SPF ranged from 1.4% to 38.4%, mean 8.8%, S D 7.0%. HR-and H R + / -lymphomas had higher SPFs than H R + lymphomas (P = .02). Four of the 10 HR-lymphomas had SPF greater than 20% as compared with only 4 of the 86 H R +/-or H R + lymphomas (P = .004).
RESULTS
Ten
SPF correlated well with Working Formulation. In low-, intermediate-, and high-grade malignant lymphomas the mean SPFs were 4.3% (SD, 2.8%), 8.4% (SD, 5.4%) and 14.6% (SD, 8.5%), respectively ( Table 2) . Only 1 (3%) of the 35 low-grade malignant and 7 (21%) of the 34 intermediate malignant lymphomas had a large SPF (> 12%, see below), whereas 15 (56%) of the 27 high-grade malignant lymphomas had SPF greater than 12% (P < .0001). H R expression or DNA ploidy did not correlate significantly with the histologic classification used.
HR expression and DNA content analysis in predicting survival. DNA aneuploidy was not associated with survival if the near-diploid cases were grouped together with the aneuploid lymphomas (P = .84), or if they were classified together with the diploid lymphomas. None of the DNA index values were useful in prediction of the final outcome. However, SPF was strongly associated with both crude and corrected survival rate. After a series of calculations, the SPF value 12% was found to be associated with most predictive power. Only 26% of the patients with lymphoma with SPF greater than 12% were alive 5 years after the diagnosis, whereas 51% of the patients with a lymphoma with less than 12% S phase cells were alive (P = .006, Fig SA) .
H R expression was also a significant factor determining the overall survival. Eighty percent of patients with H Rlymphoma survived for 5 years as compared with 44% of H R + / -and H R + lymphomas (P = .03, Fig 5B) .
Prognosis of HR-lymphomas was good even if the lymphoma had a large SPF, suggesting a rapid proliferation rate (Fig 6) . Eleven of the 12 patients with an H R + or a H R + / -lymphoma with greater than 15% S phase cells died within 3 years from the diagnosis, whereas only 1 of 5 such patients with a HR-lymphoma died (P = .01). The corrected 5-year survival rate of the patients with H R + or HR + / -lymphoma with S P F greater than 12% was only 13%, whereas 61% of the patients with lymphoma with either negative H R or S P F less than 12% survived for 5 years (P = .0001, Fig 7) . Presence of B symptoms (P = .16) did not correlate with survival, but advanced stage (P < .0001), extralymphatic site (P = .02), age greater than 40 years at diagnosis (P = .03), and male sex (P = .04) were associated with unfavorable outcome in univariate analyses. In multivariate analysis, the only independent prognostic factors were stage (P < .001), SPF (<12% v>12%, P = .002), and H R (HRv H R + / -a n d H R + , P = .003).
DISCUSSION
H R and SPF were found to be valuable prognostic factors predicting survival in non-Hodgkin's lymphoma. Paraffinembedded tissue was used for analysis, because then long follow-up was available. However, this puts some limitations for detailed phenotyping of lymphomas, because many antibodies working on frozen tissues do not stain paraffinembedded samples. This is the case also with Hermes series of MoAbs. Only Hermes-3 antibody, which identifies different epitopes of H R molecule(s) than Hermes-1 and -2, stains HRs in paraffin-embedded tissue. Another difficulty in retrospective series is that the known final outcome may influence sample classification. This was solved by sample coding.
Only 10% of lymphomas stained negatively for HR. This may reflect the fact that most normal counterparts of malignant lymphocytes have HRs, and only nonmigratory lymphocytes, eg, most germinal center cells and cortical thymocytes, lack HRs. However, the HR-lymphomas form an important subgroup because they usually remain local, even if they have an unfavorable histologic type and a large SPF (Table 1, Fig 6 ) . Therefore, many of these lymphomas may be curable with local therapy, such as radiotherapy (Table l) , and aggressive chemotherapy often recommended for high-grade malignant lymphomas can be avoided.
At least 2, possibly 3, of the 10 HR-lymphomas gave rise to hematogenous metastases (Table 1) . Tumor heterogeneity may partially explain this, since in one such case staining for H R was repeatedly negative from the primary sample, but repeatedly positive from a sample taken from a recurrent tumor. Lymphomas classified as + / -for H R behaved more like H R + lymphomas than HR-lymphomas, suggesting that if even a small proportion of lymphoma cells possess a functional HR, lymphoma can disseminate hematogenously. About 30% of H R + lymphomas remained local during the follow-up. Hermes-defined CD44 class of H R molecules alone may not be sufficient for lymphoma dissemination, but other molecules, such as, for example, the human equivalent of mouse lymphocyte homing receptor (MEL-14), the VLA-4 molecule involved in lymphocyte binding to mucosal HEV, and CD1 la/CD18 complex (LFA-I), may be needed.24s25 The CDI la/CDI 8 complex has been shown to be involved also in normal lymphocyte binding to high endothelial venules in a nonorgan-specific m a n r~e r .~~,~' Further, immunohistologic detection of a molecule does not assure its normal function; the HRs in these lymphomas may be nonfunctional. On the other hand, also early treatment or host defense mechanisms might have inhibited lymphoma dissemination in these cases.
However, a major reason for some of the H R + lymphomas not giving rise to hematogenous metastases is probably the relatively short follow-up. All patients with H R + lymphoma with a high SPF died within a few years (Fig 6 ) . Despite its protracted clinical course, low-grade lymphoma is often an eventually incurable disease, and many of the H R + lymphomas with low SPF are likely to recur later. It will be of interest to see if HR-low SPF lymphomas form a genuinely curable subgroup of low-grade lymphoma.
In conclusion, the present study indicates that meaningful lymphocyte H R and SPF analyses can be done from paraffinembedded archival material, even the fresh tissue would be ideal. H R -non-Hodgkin's lymphomas only seldom disseminate hematogenously, although they are often highly malignant and have a large fraction of proliferative cells. They also may be curable by local treatment. Both lymphocyte CD44 class of H R and SPF determinations are important and independent prognostic factors in non-Hodgkin's lymphoma.
